Physician profile
Matt S Ashley
NPI 1013294941
$211,597.79
in general payments reported to CMS, 2019-2025
29 companies · $48K in 2025
The $48K reported for 2025 was more than what 98% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,288 · 2020: $228 · 2021: $39K · 2022: $117K · 2023: $624 · 2024: $4,616 · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $38K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $1,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $37,950.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,612.50 |
| Food and Beverage | $1,323.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $199,948.97 | 2021-2025 | Urolift, Barrigel |
| Corbin Clinical Resources | $4,500.00 | 2024 | |
| Boston Scientific Corporation | $3,119.07 | 2023-2025 | General - Pelvic Organ Prolapse, Spaceoar System, Spaceoar Vue System - 10ml |
| Neotract INC. | $1,326.03 | 2019-2020 | |
| Procept Biorobotics Corporation | $871.60 | 2019-2024 | Aquabeam System |
| Teleflex Incorporated | $331.35 | 2022 | |
| Dendreon Pharmaceuticals LLC | $259.71 | 2019-2025 | Provenge |
| Endo Pharmaceuticals INC. | $204.96 | 2019 | |
| Teleflex Medical Incorporated | $171.59 | 2023 | Rusch |
| Coloplast Corp | $141.82 | 2022-2023 | Titan |
| Bayer Healthcare Pharmaceuticals INC. | $88.91 | 2023-2025 | |
| Bk Medical Holding Company INC. | $73.00 | 2023 | Bk3000, Bk3500 & Bk5000 Ultrasound System |
| Myriad Genetic Laboratories, INC. | $69.31 | 2021-2023 | Prolaris |
| Astellas Pharma US INC | $65.00 | 2021 | |
| Tolmar, INC. | $52.84 | 2025 | Eligard, Jatenzo, Rubraca |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $48.84 | 2023-2025 | Jelmyto |
| Sumitomo Pharma America, INC. | $46.59 | 2025 | Orgovyx, Gemtesa |
| Agiliti Surgical, INC. | $46.50 | 2023 | Dornier Thulio, Sonablate |
| Karl Storz Endoscopy-America | $35.17 | 2025 | |
| Progenics Pharmaceuticals, INC. | $29.79 | 2025 | |
| Ambu INC. | $27.27 | 2023 | |
| Abbvie INC. | $26.17 | 2024 | |
| Edap Technomed INC | $19.25 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $18.48 | 2025 | |
| Janssen Biotech, INC. | $18.23 | 2024 | Erleada |
| Angiodynamics, INC. | $16.67 | 2023 | Nanoknife |
| Profound Medical Corp. | $14.99 | 2022 | |
| Pfizer INC. | $13.86 | 2021 | |
| Travere Therapeutics, INC. | $11.82 | 2019-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matt Ashley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.